diabetic%20ketoacidosis%20-and-%20hyperosmolar%20hyperglycemic%20state
DIABETIC KETOACIDOSIS & HYPEROSMOLAR HYPERGLYCEMIC STATE
Diabetic ketoacidosis is characterized by having blood glucose >13.9 mmol/L, arterial pH <7.3 in adults or venous pH <7.3 in pediatrics, bicarbonate <15 mEg/L, moderate ketonuria or ketonemia and anion gap >14.
Hyperosmolar Hyperglycemic state in adults is described as having blood glucose >33.3 mmol/L, arterial pH >7.3, bicarbonate >15 mEq/L, mild ketonuria or ketonemia, effective serum osmolality >320 mOsm/kg and variable anion gap.
While hyperosmolar Hyperglycemic state in pediatric patients have blood glucose >33.3 mmol/L, venous pH >7.3, bicarbonate >15 mEq/L and altered mental status or severe dehydration.

Monitoring

Adult diabetic ketoacidosis (DKA)

  • Check glucose, blood urea nitrogen (BUN), creatinine, & electrolytes every 2-4 hours until stable
  • Continue to investigate precipitating causes & treat appropriately

Criteria for Resolution of DKA:

  • Blood glucose <200 mg/dL
  • Venous pH >7.3
  • Bicarbonate ≥15 mEq/L

After Resolution of DKA:

  • If patient is nothing by mouth/non per os (NPO), continue intravenous (IV) insulin & supplement w/ Regular insulin subcutaneous (SC) as required every 4 hours

Once patient is able to eat:

  • Start multidose insulin regimen & adjust as required
  • IV insulin should be continued for 1-2 hours after SC insulin is started

Adult hyperosmolar hyperglycemic state (HHS)

  • Check BUN, creatinine, electrolytes, & glucose every 2-4 hours until stable
  • Continue to investigate precipitating causes & treat appropriately

After Resolution of HHS:

  • If patient is NPO continue IV insulin & supplement w/ SC insulin as required

Once patient is able to eat:

  • Start multidose insulin regimen (such as SC), or give as previous treatment & check metabolic control

Pediatric DKA & HHS

  • Check glucose & electrolytes every 2-4 hours until stable
  • Continue to investigate precipitating causes & treat appropriately

After Resolution of DKA:

  • Start SC insulin (0.5-1 U/kg/day)
    • Give 2/3 of the total daily dose in the AM (1/3 short-acting & 2/3 of dose intermediate-acting insulin)
    • Give 1/3 of total daily dose in the PM (1/2 short-acting & 1/2 of dose intermediate-acting insulin)
  • Or give 0.1-0.25 U/kg SC of Regular insulin every 6-8 hours for the first 24 hours to determine insulin requirements
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.